Bio


My global research goal lies in exploring multiple imaging modalities using novel molecular contrast agents to address current unmet clinical needs with a large emphasis on ultrasound and magnetic resonance imaging. Primarily focused on developing imaging agents for disease early detection (i.e., inflammation, breast and pancreatic cancers) and treatment response monitoring in pre-clinical studies, I also explore targeted theranostic agents.

Professional Education


  • Doctor of Philosophy, University of Bordeaux, Bordeaux, France (2019)
  • Master of Science, Claude Bernard University, Lyon, France (2015)
  • Bachelor of Science, Claude Bernard University, Lyon, France (2013)

Stanford Advisors


All Publications


  • Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer. Bioengineering & translational medicine Jugniot, N. n., Bam, R. n., Meuillet, E. J., Unger, E. C., Paulmurugan, R. n. 2021; 6 (1): e10183

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is often associated with a poor prognosis due to silent onset, resistance to therapies, and rapid spreading. Most patients are ineligible for curable surgery as they present with advanced disease at the time of diagnosis. Present diagnostic methods relying on anatomical changes have various limitations including difficulty to discriminate between benign and malignant conditions, invasiveness, the ambiguity of imaging results, or the inability to detect molecular biomarkers of PDAC initiation and progression. Therefore, new imaging technologies with high sensitivity and specificity are critically needed for accurately detecting PDAC and noninvasively characterizing molecular features driving its pathogenesis. Contrast enhanced targeted ultrasound (CETUS) is an upcoming molecular imaging modality that specifically addresses these issues. Unlike anatomical imaging modalities such as CT and MRI, molecular imaging using CETUS is promising for early and accurate detection of PDAC. The use of molecularly targeted microbubbles that bind to neovascular targets can enhance the ultrasound signal specifically from malignant PDAC tissues. This review discusses the current state of diagnostic imaging modalities for pancreatic cancer and places a special focus on ultrasound targeted-microbubble technology together with its clinical translatability for PDAC detection.

    View details for DOI 10.1002/btm2.10183

    View details for PubMedID 33532585

    View details for PubMedCentralID PMC7823123

  • Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer BIOENGINEERING & TRANSLATIONAL MEDICINE Jugniot, N., Bam, R., Meuillet, E. J., Unger, E. C., Paulmurugan, R. 2020

    View details for DOI 10.1002/btm2.10183

    View details for Web of Science ID 000569340100001